UBS Group Cuts Eli Lilly And Co (LLY) Price Target to $100.00

Eli Lilly And Co (NYSE:LLY) had its price objective trimmed by UBS Group from $107.53 to $100.00 in a research note released on Friday morning, The Fly reports. The brokerage currently has an average rating on the stock.

Several other equities research analysts have also issued reports on LLY. Barclays upped their price target on Eli Lilly And Co from $112.00 to $120.00 and gave the company an overweight rating in a research report on Friday, October 12th. Cantor Fitzgerald reissued a buy rating and set a $128.00 price target on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Wolfe Research initiated coverage on Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a market perform rating and a $119.00 price target on the stock. Credit Suisse Group raised Eli Lilly And Co from an underperform rating to a neutral rating in a research report on Wednesday, October 31st. Finally, ValuEngine downgraded Eli Lilly And Co from a buy rating to a hold rating in a research note on Tuesday, November 6th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly And Co has an average rating of Buy and a consensus price target of $111.41.

LLY stock opened at $118.01 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. The company has a market cap of $125.67 billion, a P/E ratio of 21.26, a PEG ratio of 1.91 and a beta of 0.37. Eli Lilly And Co has a 12-month low of $74.51 and a 12-month high of $121.84.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Sell-side analysts expect that Eli Lilly And Co will post 5.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be paid a dividend of $0.645 per share. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a yield of 2.19%. The ex-dividend date is Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio is presently 40.54%.

In related news, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction on Monday, November 19th. The stock was sold at an average price of $115.31, for a total transaction of $22,485,450.00. Following the completion of the transaction, the insider now directly owns 118,505,584 shares in the company, valued at approximately $13,664,878,891.04. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 817,843 shares of company stock valued at $94,595,335. 0.11% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in LLY. Athena Capital Advisors LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter worth $26,000. Larson Financial Group LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter worth $29,000. Ironwood Financial llc bought a new position in shares of Eli Lilly And Co in the fourth quarter worth $30,000. Acima Private Wealth LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter worth $33,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter worth $34,000. 80.84% of the stock is owned by institutional investors.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: The risks of owning bonds

The Fly

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply